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A B S T R A C T
The aim of this study was to analyze the association between single nucleotide polymorphism (SNP) in IL1B (rs1143
634) and IL1RN (rs2234677) with chronic low back pain (LBP) in chronic post-traumatic stress disorder (PTSD). A total
of 406 war veterans from 1991–1995 war in Croatia participated in this study. They were divided into four groups, ac-
cording to psychiatric interview, psychometric testing and the presence of LBP, verified by the imaging of lumbar area,
into: (i) war veterans suffering from PTSD and LBP (N=102), (ii) war veterans suffering from PTSD only (N=108), (iii)
war veterans suffering from LBP only (N=99) and (iv) healthy controls (N=97). Each subject provided a blood sample
for IL1B and IL1RN polymorphism testing. We found no association of rs1143634 in IL1-B with LBP. Permutation test
showed significant association of rs1143634 in IL1-RN with LBP group and presence of wild type allele A was protective
in LBP group. The same SNP (rs1143634) in IL1-B was associated with the intensity of pain. No other associations were
observed between these two markers and self-reported measures evaluating PTSD and pain symptoms. These results
suggest the potential role of cytokine network in the pathogenesis of chronic PTSD and LBP, although the direct caus-
ative pathway remains unclear. The alteration of cytokine network on the level of the brain, spinal medulla and the spine
may be responsible for modulation of pain and the occurrence of LBP.
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Introduction
The chronic post-traumatic stress disorder (PTSD) is
defined as a psychiatric disorder occurring after experi-
encing the extreme traumatic stress and manifesting
with three clusters of symptoms lasting more than 3
months: persistent re-experiencing of the traumatic event,
persistent avoidance of various stimuli or numbing of
general responsiveness and increased arousal lasting
more than 3 months1. Although the majority of patients
suffering from chronic PTSD achieve certain remission
across period of several years, nearly 40% of them suffer
from life-long PTSD2.
Chronic PTSD is associated with various somatic co-
morbidities, ranging from autoimmune disorders to car-
diovascular and pain disorders3. Although some previous
reports have implied a link between chronic pain and
PTSD, a recent epidemiological study (National Comor-
bidity Survey-Replication, NCS-R) has strengthen these
findings and established plausible association between
PTSD and chronic pain disorders4. In a sample of 5366
subjects higher risk has been shown for chronic pain con-
dition in PTSD patients in contrast to subject who have
not met the criterion of traumatic event for PTSD. In the
same study, subjects that have experienced traumatic
event, but do not suffer from PTSD, had lower but still
significant risk for chronic pain condition in contrast to
subject who have not met the criterion of traumatic
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event. Although the association between chronic pain
and chronic PTSD is thus well established, few attempts
were made to provide the biological insight in the role of
pain mechanisms in chronic combat-related PTSD.
One of the possible pathways of revealing pain mecha-
nisms in the chronic PTSD is by investigating cytokines
known to be involved in the pain modulation. The activ-
ity of cytokine network has role in the pathogenesis of
LBP, mainly in the lumbar disc degeneration and other
phases such as protrusion, extrusion etc. Akyol et al. ha-
ve shown higher expression of several cytokines; IL-1B,
IL-2, IL-4, IL-10 in degenerated lumbar disc5. Astrocytes
are believed to be the main source of inflammatory
cytokines by activating various signalling pathways in
the model of LBP6. IL-1 receptor antagonist (IL-1RN),
derived from the same precursor peptide as IL-1B, is
found to have protective role in LBP pathogenesis, main-
ly by down-regulating the expression of various matrix
metalloproteinases7, so one can conclude that the antag-
onistic relationship between these two cytokines is asso-
ciated with LBP. Furthermore, IL-1RN has been linked
with a severity of knee osteoarthritis according to a re-
cent meta-analysis8. So far there was only one attempt to
link acute LBP and genetic markers of IL-1B (rs1143
634), located on 5th exon (CS –›T), and IL-1RN (rs2234
677), located in 5’ untranslated region (G –›A), which
were found to be associated with the intensity and dura-
tion of pain9.
The aim of this study was to investigate the associa-
tion of genetic polymorphism in IL-1B and IL-1RN with




A total of 536 subjects were initially involved in this
study. They were selected to represent a population of
Croatian Homeland war veterans, aged 35–54 years, who
were exposed to the direct combat conditions as frontline
soldiers for at least 3 consecutive months. The subjects
were included in the present study by the means of con-
secutive enrolment from the Clinic for Psychological
Medicine in Zagreb and various by direct contact with
some of the veterans’ nongovernmental organizations in
Croatia. We aimed to create four study groups of approxi-
mately same size of 100 subjects:
1. War veterans suffering from chronic PTSD and low
back pain (LBP)
2. War veterans suffering from chronic PTSD only
3. War veterans suffering from chronic LBP only
4. Healthy controls (war veterans who were at the
time of study showing none of these disorders
(healthy controls)
In order to classify the subjects into these four groups,
we undertook a number of diagnostic procedures. Firstly,
all subjects were interviewed by an experienced psychia-
trist at the Clinic for Psychological Medicine, University
Hospital Centre, Zagreb to assess the presence of PTSD
according to DSM-IV-TR criterion1. Additional psycho-
metric testing was also performed, aiming to provide a
more detailed overview (detailed explanation provided in
the next section). Subjects with positive anamnesis of
head and spinal injury, acute psychosis, alcohol or illegal
substance abuse or those who were diagnosed with any
form of the psycho-organic syndrome were excluded from
the study. After establishing a PTSD status, we pro-
ceeded to classify them according to the LBP status. Ini-
tial criterion was the presence of LBP was defined as
pain with a minimal duration of 12 months. Subjects who
reported suffering from LBP were then directed to a spe-
cialist surgeon at the Clinic for Traumatology Zagreb, for
further clinical and radiographic testing by means of
magnetic resonance imaging. Those who were found to
have any form of the organic cause for LBP (to exclude
those suffering from lumbar disc protrusion, extrusion,
herniation and spinal stenosis) were excluded from sub-
sequent analyses. By doing this, we were able to classify
all subjects into positive or negative PTSD and LBP
group. Subjects who had no indication of PTSD nor re-
ported LBP were considered to be healthy controls.
Each subject has given an informed consent and the
study was conducted by ethical principles set by WMA
Declaration of Helsinki, and the entire study was ap-
proved by the Ethical Board of the Clinic for Trauma-
tology, University Hospital Centre »Sestre Milosrdnice«
Zagreb, Croatia.
Questionnaires
General questionnaire was developed to assess basic
demographics, LBP status and psychiatric data. Items
assessing LBP included various risk factors such as weight,
height, body mass index, vocational and avocational ac-
tivity, various LBP descriptors such as duration of symp-
toms, intensity, and potential use of analgesic medica-
tions. Items analyzing PTSD included duration PTSD,
onset of symptoms, other comorbid psychiatric disorders,
psychotropic medication, war exposure, short description
of traumatic events, medications.
Trauma Symptom Inventory-A
Trauma Symptom Inventory-A (TSI-A) is a specific
self-reported measure developed to evaluate the acute
and chronic symptomatology of PTSD, regardless of the
traumatic event, which may include combat experience,
rape, childhood abuse, natural disaster, physical assault
etc10. TSI-A is a shorter version of the original Trauma
Symptom Inventory. TSI-A consists of 86 items in the
form of a four-point scale with symptoms rated retro-
spectively within the preceding six months through ans-
wers varying from »0«, denoting »never«, to »3«, denoting
»often«. On the basis of this questionnaire, the following
clinical scale evaluating specific symptoms was obtained:
Anxious Arousal, Depression, Anger/Irritability, Intru-
sive Experiences, Defensive Avoidance, Dissociation, Im-
paired Self-Reference and Tension Reduction Behaviour.
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An adequate internal validity was found on a sample of
war veterans suffering from PTSD with Cronbach á varying
from 0.73 to 0.91, depending on the scale11. This measure was
reported to correctly classify 85.5% of PTSD cases and
has shown similar results for other measures evaluating
PTSD in a community sample12.
Short Form McGill Pain Questionnaire
The Short Form McGill Pain Questionnaire (SFMPQ)
was used to assess specific characteristics of LBP13. It is
based on two factor model of pain which distinguish the
pain perception as sensory or affective. This inventory
consists of 16 items; 11 items assessing sensory pain and
4 items assessing affective pain. Each item consists of a
word or phrase depicting the pain experience with an-
swer ranging from »0«, denoting »absence of particular
pain«, to »3«, denoting »severe pain«. Separate item mea-
sures overall intensity of pain, ranging from »0« to »5«.
Internal consistency of this scale varied from 0.705 to
0.82, depending on the sample14,15, although most of the
studies do not measure Cronbach’s a while using this
inventory16. The authors of this study have not found
specific cut off values of SFMPQ used in PTSD patients
in literature review.
Radiographic methods
In order to exclude subjects with detectable organic
causes of LBP, magnetic resonance imaging by 1.5 T
Magnetom Symphony (Siemens Medical System) was
used. T1 weighted scans were used to assess anatomic re-
lations and T2 weighted scans were used to assess patho-
logic change of signal. Repetition time totalled 510–810
ms; echo time 14–17 ms. The slice thickness was 2–3 mm.
Field of view was 120–180 mm, with matrix of 512x256.
In order to suppress possible bias, radiologists were un-
aware of the patient’s conditions and were asked to re-
port the presence of lumbar disc degeneration, protru-
sion, herniation and spinal stenosis.
Genotyping SNPs in IL-1B (rs1143634)
and IL-1RN (rs2234677)
Each subject has given a blood sample (3 mL) that
was collected in labelled test tube and kept on –20 °C.
DNA extraction was carried out by G-spin Genomic DNA
Extraction Kit (iNtRON Biotechnology). SNP genotyp-
ing was performed using real-time PCR, TaqMan probes
and technology (Applied Biosystems). Specific probes for
each SNP were obtained; C_9546517_10 for SNP in
IL-1b (rs1143634) and C_11948096_10 for SNP in IL-1RN
(rs2234677). A probe for wild type allele was labeled by
VIC® color and a probe for mutant allele was labeled by
FAM™ color. The genotypes were determined by Taq-
Man® assay (Applied Biosystems), according to manufac-
turer’s recommendations, but scaled to final PCR vol-
ume of 12.5 mL. The real-time PCR and discrimination of
alleles was performed on ABI PRISM® 7000 Sequence
Detection System (Applied Biosystems). The reaction
conditions were following; 95 °C for 10 min, 45 cycles at
92 °C for 15 sec and at 62 °C for 10 min. A laboratory
analysis was performed as a double blind experiment
with a negative and positive control on the reaction
plate. For each sample same procedure was used.
Statistical analysis
After collecting the data, various descriptive methods
were used; means, standard deviations, frequencies and
percents. Before parametric analysis, Kolmorogov-Smir-
nov test was used distribution of data. T-test for inde-
pendent sample and analysis of variance followed by post
hoc Tukey HSD were used for parametric data. c2-test
and Pearson correlation factors were used for categorical
data.
TSI-A and SFMPQ scales were transformed into bi-
nary variables. Transformation was obtained by taking
25 upper percentiles of participants with highest inten-
sity of subjects’ symptoms as cases, while other 75% of
subjects served as controls. Logistic regression analysis
was performed with age and group as independent vari-
ables as controls.
In the analysis of genetic data usual approach to pair
analysis was used, followed by permutation test. Hardy-
-Weinberg equilibrium was assessed by c2-test.
A priori statistical power analysis was performed be-
fore the study conduction in order to estimate the sample
size. Based on these assumptions, the total size of each
group was calculated with statistical power of 80% and
statistical significance of 0.05. Each group had to contain
minimum of 92 subjects, with total sample size being 364.
Following programs were used for statistical analysis:
Statistical Package for Social Science 14.00 (SPSS) and
PLINK 1.0017.
Results
A total 541 participants initially responded to partici-
pate in this study. After application of exclusion criteria,
withdrawal for personal reasons and due to unsuccessful
genotyping, the final sample consisted of 406 partici-
pants. These participants were subsequently classified in
four groups, according to the presence of post-traumatic
stress disorder and lower back pain: war veterans suffer-
ing from chronic PTSD and LBP (N=102), war veterans
suffering from chronic PTSD only (N=108), war veter-
ans suffering from chronic LBP only (N=99) and healthy
controls (war veterans who were at the time of study
showing none of these disorders; N=97). The comparison
of the basic characteristics of these samples indicated
strong differentiation in most cases (Table 1). Further-
more, these groups differed strongly in the number of
children in the family (c2=80.93, p<0.001), employment
status (c2=90.44, p<0.001), smoking (c2=17.03, p<0.001),
wine consummation (c2=72.11, p<0.001), and spirits
consummation (c2=39.10, p<0.001).
Self-perceived chronic pain and PTSD symptoms
The comparison of the four domains of pain also indi-
cated the existence of strong group differences, with
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TABLE 1
THE ANALYSIS OF SOCIAL AND DEMOGRAPHIC NUMERICAL VARIABLES












PTSD 41.56 4.25 35.00 54.00
LBP 48.35 5.14 35.00 54.00
Controls 41.44 5.20 35.00 54.00
Height (cm)
PTSD+LBP 178.12 7.22 158.00 191.00
<0.001 1–2, 2–3PTSD 182.81 5.36 170.00 192.00
LBP 178.25 8.13 160.00 200.00
Controls 180.53 5.85 168.00 192.00
Mass (kg)
PTSD+LBP 85.79 13.53 46.00 130.00
0.423 –PTSD 84.74 10.89 45.00 130.00
LBP 87.60 13.35 55.00 130.00
Controls 86.07 11.47 64.00 120.00
BMI (kg/m2)
PTSD+LBP 27.04 4.03 18.43 40.12
<0.001 1–2, 2–3PTSD 25.37 3.31 14.53 43.94
LBP 27.60 4.17 17.96 46.06
Controls 26.67 3.13 20.45 34.68
LBP – low back pain, BMI – body mass index, groups 1 – PTSD+LBP, 2 – PTSD, 3 – LBP, 4 – controls, statistical significance cut off
p<0.001
TABLE 2
THE DIFFERENCE BETWEEN THE GROUPS ACCORDING TO SFMPQ FACTORS








PTSD 1.92 1.94 0 12
LBP 13.74 9.11 0 33
Controls 2.31 2.42 0 9
Affective pain




PTSD 0.69 0.82 0 3
LBP 2.63 3.44 0 12
Controls 0.30 0.62 0 3
Total pain




PTSP 2.59 2.30 0 15
LBP 16.36 11.08 0 45
Controls 2.32 2.15 0 9
Evaluation
of pain




PTSP 0.28 0.50 0 2
LBP 3.14 0.98 0 5
Controls 0.34 0.50 0 5
SFMPQ – Short Form McGill Pain Questionnaire, LBP – low back pain, groups 1 – PTSD+LBP, 2 – PTSD, 3 – LBP, 4 – controls, statis-
tical significance cut off p<0.001
pair-wise insignificant differences recorded between pa-
tients with PTSD and controls, while those with physical
symptoms reported much higher levels of pain sensation
(Table 2).
PTSD groups have not varied in factors obtained from
TSI-A questionnaire. The linear regression analysis pre-
dicting the factors obtained from SFMPQ by TSI-A, age
and group variables in groups suffering from chronic
LBP showed the statistical significance (p<0.001) for all
four factors; »sensory pain« (R2=67.9), »affective pain«
(R2=63.0) and »evaluation of pain« (R2=64.5). The age
and most of TSI-A variables were not significant as pre-
dictors, except »depression« (F=5.16, p=0.024) and »in-
trusive experience« (F=5.09, p=0.025) in prediction of
»affective pain«, while belonging to the particular group
was significant at p<0.001 for »sensory pain« (F=
197.21), »affective pain« (F=92.77) and »evaluation of
pain« (F=108.22).
The frequencies of IL-1b (rs1143634) and IL-1RN
(rs2234677) genotypes showed no difference among the
four study groups for IL-1b (c2=1.35, P=0.853), while
that for IL-1RN was marginally significant (c2=9.61,
p=0.048; Table 3).
The comparison of the participants suffering from
LBP with the controls by using permutation test has
shown borderline significance for IL-1RN (rs2234677)
(p=0.049), unlike for IL-1b (rs1143634) (p=0.573). While
comparing the LBP group to allele differences the associ-
ation was found with for IL-1RN (rs2234677) (p=0.041,
OR=0.63 95%CI [0.40–0.98]).
The use of logistic regression for the final analytic
step indicated the lack of significant association of IL-1b
SNP with pain intensity (adjusted for age and gender ef-
fects), with the exception of evaluation of pain, which
seemed to be significantly associated with this genetic
marker (Table 4).
Discussion
The association of SNP IL-1RN (rs2234677)
with LBP in war veterans without PTSD
We demonstrated the possible association of SNP in
IL-1RN (rs1143634) with a group of war veterans suffer-
ing from chronic LBP without comorbid PTSD. The rea-
sons of our finding may be multiple, varying from unre-
cognised confounding factors to different pathogenesis of
chronic pain in PTSD.
Our findings may be in accordance with the patho-
genesis of chronic LBP uncomplicated with psychiatric
disorders with distinct pain features. One of the main
paradigms concerning this disorder is central senzitation
on the level of spinal cord. One of the possible mecha-
nisms is through modulated N-Methyl-D-aspartate
(NMDA) excitatory pathways, resulting in neurotoxicity,
changes in neuroplasticity and prolonged hyperalgesia of
dorsal horns18. Numerous data, varying from using
NMDA antagonist in animal models evoke algesia (al-
though the data of their usage in human subjects is
scarce) to measuring mRNA levels in the neuropathic
pain, have confirmed this hypothesis as the most plau-
sible19,20. Recent studies have shown the association of
hyperactivity of NMDA activity and overexpression of
IL-1B in spinal cord21. Second possible mechanism of
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TABLE 3
THE FREQUENCIES OF IL-1B (RS1143634) AND
IL-1RN (RS2234677)
IL-1B (rs1143634)
Group N / % CC CT TT
PTSD + LBP
N 57 39 4
% 57.0 39.0 4.0
PTSD
N 67 32 6
% 63.8 30.5 5.7
LBP
N 55 35 3
% 59.1 37.6 3.2
Controls
N 55 37 4
% 57.3 38.5 4.2
Total
N 234 143 17




N 63 31 5
% 63.6 31.3 5.1
PTSD
N 51 37 13
% 50.5 36.6 12.9
LBP
N 47 42 10
% 47.5 42.4 10.1
Controls
N 61 29 4
% 64.9 30.9 4.3
Total
N 222 139 32
% 56.5 35.4 8.1
TABLE 4
THE ASSOCIATION OF IL-1B (RS1143634) WITH PAIN INTENSITY
IL-1ß Sensory pain Affective pain Total pain Evaluation of pain
CC* 0.406 1.00 0.419 1,00 0.639 1.00 0.006 1.00
CT 0.299 0.71 [0.37–1.36] 0.448 0.72 [0.31–1.68] 0.564 0.82 [0.42–1.61] 0.001 0.20 [0.07–0.54]
TT 0.488 1.89 [0.31–11.46] 0.342 2.82 [0.33–23.99] 0.511 1.86 [0.29–11.89] 0.392 0.36 [0.03–3.80]
IL-1B hyperactivity is induction through toll-like recep-
tors expressed on astrocytes and microglia stimulated by
noxious stimuli, resulting in positive feedback loop22.
Further evidence of IL-1 cytokines family involvement in
the mechanisms of spinal cord central senzitation lies in
animal studies, where applying IL-1RN was used to at-
tenuate hyperalgesia23. This data indirectly support our
hypothesis of IL-1 gene locus involvement in chronic
LBP.
The issue arising in interpretation of our findings lies
in the lack of association of SNP in IL-1RN (rs2234677)
with a group of war veterans suffering from PTSD and
LBP contrary to the war veterans suffering from only
LBP. This could be explained by altered pain processing
in PTSD. Geuze et al. have first published preliminary
results of hyperactivation of anterior cingulated cortex
(ACC), right putamen and bilateral insula accompanied
with decreased activation of right precentral gyrus and
the right amygdala by fMRI imaging of pain processing
in war veterans suffering from PTSD24,25. Interestingly,
they found reduced sensitivity to standard pain stimulus,
but increased reactivity above the pain threshold. These
findings of distinct pain sensitivity were replicated by
Defrin et al.26. PET study using (11C) cartefanil in PTSD
war veterans has found reduced m-opioid levels in amyg-
dala, nucleus accumbens, and dorsal frontal and insular
cortex27.
These imaging data suggest altered pain processing in
PTSD, although our literature search through relevant
databases have not found imaging studies in veterans
suffering from both PTSD and chronic pain in order to
compare with the pain processing in patients suffering
from chronic pain only. We hypothesize that there is a
likely possibility that LBP in patients suffering from
PTSD is, somewhat, distinct syndrome, different than
LBP in war veterans without PTSD. Based on both epi-
demiological and imaging studies of chronic pain in
PTSD, it seems that the main pathogenic moment lies in
the alteration of brain circuits involved in sensory, cogni-
tive and affective pain processing, while in LBP without
comorbid PTSD pathogenesis lies in the central sen-
zitation of spinal cord, therefore cytokine network. This
could explain our findings, perhaps contradictory at first
glance, but more studies are needed to confirm this sug-
gestion.
The of association between SNP in IL-1B
(rs1143634) and self- reported pain questionnaire
SNP in IL1B (rs1143634) was associated with »pain
evaluation« – pain intensity on scale from 1 to 5, while
both SNPs were not associated with »affective pain« nor
»sensory pain« factors derived from Melzack’s SFMPQ.
The issue in the interpretation of our results is the
lack of association of SNP in IL-1RN (rs2234677) and
self-reported scale of SFMPQ. To explain this one must
consider the definition of pain provided by International
Association for Study of Pain (IASP), which focuses on
pain as a primarily subjective feeling28. We have tried to
divide LBP, perhaps semi-successfully, into two entities;
the first being objective clinical diagnosis made by psy-
chiatrist, radiologist and surgeon, and the second being
subjective perception of pain, measured by SFMPQ. As
stressed out by Kerkof et al. in IL-1 locus meta-analyis of
knee and hip arthritis, the genetic studies in chronic pain
are often tricky, leading to perhaps doubtful conclusions
due to diverse phenomenology of chronic pain8. They
have shown the association of IL-1 region with the inten-
sity of knee arthritis without the association to radio-
graphic findings, showing the discrepancy of objective
and subjective state. Although objective measurement of
chronic pain29, especially functional imaging, has ad-
vanced our understanding of pain processing, it’s utility
in genetic research remains questionable, mainly be-
cause small samples and expensiveness. Use of algometry
might have enhanced our study, the authors question if
its usage would bring different results, especially in con-
text of chronic LBP. Because of the reasons explained
above, we argue for plausibility of our results suggesting
the involvement of IL-1 genetic region in LBP, especially
the association of SNP in IL1B (rs1143634) with the sub-
jective evaluation of pain. It is important to note that in
this association both LBP groups have been used in anal-
ysis.
Merits and limitations of the study
To the authors’ knowledge, this is a first study associ-
ating IL-1B and IL-RN SNPs with chronic LBP. Further-
more, this is a first association study exploring cytokine
network genetics of LBP in context of psychiatric disor-
der, such as PTSD, adding more clinical relevance to re-
search. The design of the study used more strict criteria
than usually used in chronic pain studies. While we de-
fined the duration of chronic pain as a pain lasting for
more than one year, chronic pain is usually defined as a
pain lasting for more than three months. We have used
the narrower definition in order to filtrate a possible con-
founding factor of the subjects’ pain reporting due to dif-
ferent perception of pain and recall error. In the analysis
of self-reported questionnaires only upper 25 percentiles
as cases and other 75 percentiles as controls have been
used in order to clarify results. By using two additional
groups: war veterans suffering from PTSD and healthy
war veterans, we were able to control for possible con-
founding factors such as traumatic experience, which is
currently hypothesised as being influential on the ge-
nome via epigenetic modulation30,31, although up to date
no study has investigated actual epigenetic modulation
in PTSD.
One of the possible limitation of this study was
omittance to use the semi-structured interview Clinician
Administered PTSD Scale32 in the diagnosis of PTSD,
but psychiatric interview at the time of the entrance to
the study according to DSM-IV-TR and TSI-A in order to
acquire in-depth information about association between
self-reported PTSD symptoms and chronic LBP (data not
currently published) because of the discrepancy between
clinicians’ and patients’ view of the PTSD symptoms33.
Second possible limitation is unknown Croatian genetic
Z. Lon~ar et al.: Do IL-1B and IL-1 Modulate Chronic Low Back Pain, Coll. Antropol. 37 (2013) 4: 1237–1244
1242
homogeneity, although because of European relative ge-
netic homogeneity and low migration rates, one might
assume that Croatian population is homogenous. Third
limitation was inability to achieve small effect size due to
low sample size, although most of psychiatric association
studies at molecular level had similar sample size. An-
other limitation is unknown function of SNPs used in
this study.
Conclusion
This study has offered preliminary evidence for role of
IL-1 locus in pathogenesis in LBP and indirect evidence
of altered brain circuits in pain processing in PTSD.
However, as most genetic association studies involving
several SNPs, based on specific hypothesis, it suffers
from usual pitfalls. Future research is needed in order to
replicate these findings and possibly expand knowledge
about genetic background of LBP in genome-wide associ-
ation studies in order to find possible new pathogenic
events and enhance our understanding of chronic pain in
psychiatric disorders.
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DA LI IL-1B I IL-1 MODULIRAJU DO@IVLJAJ BOLI KOD KRONI^NE KRI@OBOLJE U
PACIJENATA SA DIJAGNOSTICIRANIM POSTTRAUMATSKIM STRESNIM POREME]AJEM?
S A @ E T A K
Cilj ovog istra`ivanja je bio analizirati vezu izme|u pojedinog nukleotidnog polimorfizma (SNP) kod IL1B (rs1143
634) i IL1RN (rs2234677) s do`ivljajem boli kod kroni~ne kri`obolje (LBP) u veterana dijagnosticiranih sa posttraumat-
skim stresnim poreme}ajem (PTSP). Sudionici su bili podijeljeni u ~etiri grupe temeljem psihijatrijskog intervjua, psi-
hometrijskog tesitranja i prisutnosti boli u kri`ima. Prvu skupinu su sa~injavali ratni veterani kojima je dijagnosticiran
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PTSP i kroni~na kri`obolja (N=102), drugu skupinu su sa~injavali ratni veterani kojima je dijagnosticiran samo PTSP
(N=108), tre}u skupinu su sa~injavali ratni veterani kojima je dijagnosticirana samo krnoi~na kri`obolja (N=99), a
~etvrtu skupinu su sa~injavale zdrave kontrole (N=97). Svaki sudionik je bio prodvrgnut testiranju na IL1B i IL1RN
polimorfizme iz krvi. Provedenim analizama nije prona|ena veza izme|u rs1143634 u IL1-B sa kroni~nom kri`oboljom.
Test permutacija je pokazao zna~ajnu vezu rs1143634 u IL1-RN sa kroni~nom kri`oboljom, s time da se prisutnost
divljeg tipa alela A pokazala protektivnim faktorom kod kroni~ne kri`obolje. Pojedini nukleotidni polimorfizam
(rs1143634) kod IL1-B je pokazao vezu sa intenzitetom boli. Ovim istra`ivanjem nisu dokazane nikakve druge veze
izme|u navedenih markera i samoiskaza o mjerama PTSP-a ili bolnih simptoma. Rezultati ukazuju na potencijalnu
ulogu mre`e citokina u patogenezi kroni~nog PTSP-a i kroni~ne kri`obolje, iako direktan uzro~ni put za sada nije jasan.
Promjene u citokinskoj mre`i na razini mozga, le|ne mo`dine i kralje`nice mogu biti odgovorne za modulaciju boli i
pojavnost kroni~ne kri`obolje.
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